



TheScientist
BEST PLACES
TO WORK
INDUSTRY | 2012

TOP 20 COMPANIES

| RANK IN 2012 | RANK IN 2011 | COMPANY | # EMPLOYEES | # R&D EMPLOYEES | R&D HIRES IN 2011 | SIGNIFICANT RECENT DEVELOPMENTS |
|--------------|--------------|---|-------------|-----------------|------------------------------|--|
| 1 | - | ADInstruments Bella Vista NSW Australia | 170 | 45 | 3 in New Zealand | Made significant advances in research (LabChart) and education (LabTutor) software to include data recording from multiple devices and online delivery of experiment content, respectively |
| 2 | 1 | Epizyme Cambridge, MA | 45 | 35 | 11 | Ushered two lead programs for personalized therapeutics for patients with genetically-defined cancer into preclinical development |
| 3 | 10 | DuPont Wilmington, DE (Numbers include Pioneer Hi-Bred) | 70,000 | 9,500 | Information not available | Launched 1,742 new products and applications, including a renewably sourced high-performance polyamides family and enzyme-based offerings that extend the shelf life of bakery products |
| 4 | 9 | Wyatt Technology Santa Barbara, CA | 106 | 15 | 3 | Developed the Möbiu zeta potential instrument, which measures particle/protein charge/mobility within a range of salt and pH values inaccessible by other commercial devices |
| 5 | 11 | Vertex Pharmaceuticals Cambridge, MA | 2,047 | 1,221 | 55 | Launched its first medicine, INCIVEK® (telaprevir) tablets, for hepatitis C, in 2011. Nine months later, launched KALYDECO™ (ivacaftor)—a therapy for a subset of people with cystic fibrosis (CF) |
| 6 | - | Rib-X Pharmaceuticals New Haven, CT | 43 | 32 | 3 | Completed three phase II trials for delafloxacin, a candidate anti-biotic intended for use as a broad-spectrum, first-line treatment for infections including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) |
| 7 | 13 | Dow AgroSciences Indianapolis, IN | 7,000+ | 1,800+ | 200+ | Made plans to launch the Enlist™ Weed Control System and the sap-feeding insecticide sulfoxaflor (pending regulatory approval) |
| 8 | - | Genomatica San Diego, CA | 102 | 82 | 25 | Successfully produced butadiene from renewable feedstocks and received the EPA Presidential Green Chemistry Challenge Award in 2011 |
| 9 | - | DynPort Vaccine Company Frederick, MD | 90 | 38 | 2 | Has two vaccine candidates for the US Department of Defense—a plague vaccine (rFIV) and a botulinum neurotoxin vaccine (rBV A/B)—in the late stages of phase II trials |
| 10 | 12 | Pioneer Hi-Bred: A DuPont Business Johnston, IA (See DuPont) | N/A | N/A | Information not available | Opened a new \$40 million Beaver Creek facility with space for approximately 400 new research positions at the headquarters in Johnston, Iowa, in January 2012 |
| 11 | 7 | Celldex Therapeutics Needham, MA | 106 | 59 | 8 | Launched a phase III trial last December of rindopepimut, an immunotherapy that targets the tumor-specific oncogene epidermal growth factor variant III (EGFRvIII) in patients with surgically resected (EGFRvIII)-positive glioblastoma |
| 12 | 15 | Monsanto St. Louis, MO | 20,000+ | 5,000 | -350 | Will launch farm trials on DroughtGard Hybrids, a drought-tolerant corn that combines germplasm selected for its drought tolerant characteristics |
| 13 | 23 | Regeneron Pharmaceuticals Tarrytown, NY | 1742 | 707 | 101 | In November 2011, received approval and launched EYLEA® (afibercept) Injection—a fusion protein designed to treat patients suffering from eye disorders characterized by abnormal blood vessels and leakage of fluid in the retina and macula |
| 14 | 28 | Abbott Laboratories Abbott Park, IL | 91,000 | 10,000 | 350+ | Launched a next-generation drug-eluting stent, XIENCE PRIME, in the U.S., and introduced Absorb, the world's first bioresorbable vascular scaffold for coronary artery disease, in Europe |
| 15 | 3 | Aldevron Fargo, ND | 75 | 27 | 5 | Manufactured more than 10,000 plasmids for research, diagnostic, and clinical applications and used GENOVAC technology to develop antibodies to the erythropoietin (EPO) receptor for research into the risks of long-term EPO use |
| 16 | - | Roche Basel, Switzerland | 80,000 | 18,450 | N/A | Received approval for two new skin cancer drugs: Zelboraf and Erivedge and has treatments for multiple sclerosis and schizophrenia currently in phase III trials |
| 17 | 18 | Novartis Basel, Switzerland | 124,000 | 13,321 | 1,683 | With collaborators, discovered a new dual-acting class of antimalarial compounds with potential to both prevent and treat malaria infections and has more than 130 projects in clinical development |
| 18 | 17 | Alnylam Pharmaceuticals Cambridge, MA | 115 | 91 | 10 | Developed and advanced RNAi therapeutics by providing proof of concept data in transthyretin-mediated amyloidosis patients, who experienced robust silencing of the disease gene transthyretin (<i>TTR</i>) |
| 19 | 14 | Integrated DNA Technologies (IDT) Coralville, IA | 709 | 28 | 3 | Added 1st BASE Custom Oligos (FBCO) DNA synthesis facility in Singapore, which will provide Asian researchers access to high-quality DNA oligonucleotides with the fast turnaround times and personal customer service that operating locally makes possible |
| 20 | 27 | Bayer Corp Leverkusen, Germany | 111,800 | 13,300 | 350+ | Advanced four medicines into late-stage development: Xarelto, Alpharadin, regorafenib, and VEGF-Trap Eye |

STRENGTHS AND WEAKNESSES

| RANK | COMPANY | STRENGTHS | WEAKNESSES |
|------|---|---|---|
| 1 | ADInstruments Bella Vista NSW Australia | <ul style="list-style-type: none"> • Job Satisfaction • Management | <ul style="list-style-type: none"> • Research Environment • Communications |
| 2 | Epizyme Cambridge, MA | <ul style="list-style-type: none"> • Policies and Practices • Communications | <ul style="list-style-type: none"> • Research Environment • Training and Development |
| 3 | DuPont Wilmington, DE | <ul style="list-style-type: none"> • Integrity • Training and Development | <ul style="list-style-type: none"> • Communications • Management |
| 4 | Wyatt Technology Santa Barbara, CA | <ul style="list-style-type: none"> • Job Satisfaction • Management | <ul style="list-style-type: none"> • Training and Development • Research Environment |
| 5 | Vertex Pharmaceuticals Cambridge, MA | <ul style="list-style-type: none"> • Remuneration and Benefits • Training and Development | <ul style="list-style-type: none"> • Communications • Job Satisfaction |
| 6 | Rib-X Pharmaceuticals New Haven, CT | <ul style="list-style-type: none"> • Research Environment • Job Satisfaction | <ul style="list-style-type: none"> • Training and Development • Integrity |
| 7 | Dow AgroSciences Indianapolis, IN | <ul style="list-style-type: none"> • Training and Development • Integrity | <ul style="list-style-type: none"> • Research Environment • Policies and Practices |
| 8 | Genomatica San Diego, CA | <ul style="list-style-type: none"> • Integrity • Communications | <ul style="list-style-type: none"> • Remuneration and Benefits • Training and Development |
| 9 | DynPort Vaccine Company Frederick, MD | <ul style="list-style-type: none"> • Job Satisfaction • Communications | <ul style="list-style-type: none"> • Remuneration and Benefits • Training and Development |
| 10 | Pioneer Hi-Bred: A DuPont Business Johnston, IA | <ul style="list-style-type: none"> • Training and Development • Integrity | <ul style="list-style-type: none"> • Policies and Practices • Integrity |
| 11 | Celldex Therapeutics Needham, MA | <ul style="list-style-type: none"> • Training and Development • Policies and Practices | <ul style="list-style-type: none"> • Job Satisfaction • Integrity |
| 12 | Monsanto St. Louis, MO | <ul style="list-style-type: none"> • Remuneration and Benefits • Training and Development | <ul style="list-style-type: none"> • Communications • Research Environment |
| 13 | Regeneron Pharmaceuticals Tarrytown, NY | <ul style="list-style-type: none"> • Integrity • Training and Development | <ul style="list-style-type: none"> • Remuneration and Benefits • Communications |
| 14 | Abbott Laboratories Abbott Park, IL | <ul style="list-style-type: none"> • Policies and Practices • Training and Development | <ul style="list-style-type: none"> • Communications • Integrity |
| 15 | Aldevron Fargo, ND | <ul style="list-style-type: none"> • Job Satisfaction • Communications | <ul style="list-style-type: none"> • Remuneration and Benefits • Training and Development |
| 16 | Roche Basel, Switzerland | <ul style="list-style-type: none"> • Remuneration and Benefits • Research Environment | <ul style="list-style-type: none"> • Management • Job Satisfaction |
| 17 | Novartis Basel, Switzerland | <ul style="list-style-type: none"> • Training and Development • Remuneration and Benefits | <ul style="list-style-type: none"> • Policies and Practices • Communications |
| 18 | Alnylam Pharmaceuticals Cambridge, MA | <ul style="list-style-type: none"> • Training and Development • Communications | <ul style="list-style-type: none"> • Integrity • Policies and Practices |
| 19 | Integrated DNA Technologies Coralville, IA | <ul style="list-style-type: none"> • Management • Policies and Practices | <ul style="list-style-type: none"> • Remuneration and Benefits • Job Satisfaction |
| 20 | Bayer Corp Leverkusen, Germany | <ul style="list-style-type: none"> • Integrity • Remuneration and Benefits | <ul style="list-style-type: none"> • Research Environment • Communications |